ReNeuron

INVESTING IN CURES SUMMIT 2021

DISCLAIMER

This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Subject to certain exceptions, this Presentation is not for distribution in the United States, Australia, Canada or Japan or any other jurisdiction where its distribution may constitute a violation of the laws of such jurisdiction.

The information contained in this document ("Presentation") has been prepared by ReNeuron Group plc (the "Company") and neither this Presentation, nor the information contained in it should be considered a recommendation by the Company or any of its shareholders, directors, officers, agents, employees or advisers in relation to any purchase of the Company's securities, including any purchase of or subscription for any shares (or securities convertible into shares) in the capital of the Company. This Presentation has not been fully verified and is subject to material updating, revision and further amendment. Any person who receives this Presentation should not rely or act upon it. This Presentation should not be re-distributed, re-published, reproduced or disclosed by recipients, in whole or in part.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements and past performance is no guarantee of future performance. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, revenue generation, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000.

In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent. This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. In particular, this Presentation is for information purposes and does not constitute an offer or invitation to subscribe for or purchase any securities in the United States. The securities of the Company have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, pledged, delivered, distributed or transferred, directly or indirectly, into or in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in accordance with any applicable state securities laws. There will be no public offering of the securities of the Company in the United States.

By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer.

Lead Programme

hRPC in retinitis pigmentosa

HUMAN RETINAL PROGENITOR CELLS (hRPC)

hRPC: allogeneic cell-based therapeutic approach to retinal disease

hRPCs differentiate into functional photoreceptors and integrate into retinal layers in pre-clinical models; integration may also enable durable trophic support

Broad potential across a range of eye diseases, initially targeting inherited retinal degenerative diseases

Orphan Drug Designation in EU and US in RP and FDA Fast Track Designation

Proprietary manufacturing process and controls allow for stable, high quality and high quantity GMP production

Collaborations with Schepens Eye Research Institute (Harvard) and University College London

Proprietary technology enabled development of GMP manufacturing process

Cryopreserved formulation provides nine-month shelf life and enables local treatment worldwide

High potential

RP is a large orphan market

Mechanism of action independent of genetic cause

Commercially viable formulation

PHASE 2a EFFICACY RESULTS

Mean changes in ETDRS letters read (treated eye vs untreated eye)

	Day 30 (n=9)	Day 60 (n=9)	Day 90 (n=9)	Day 180 (n=9)	Day 270 (n=8)	Day 365 (n=7)
Treated Eye	+7.9	+8.0	+10.8	+9.6	+7.1	+9.9
Untreated Eye	+0.2	+1.2	+4.4	+3.4	+1.2	-2.4
Difference	+7.7	+6.8	+6.4	+6.2	+5.9	+12.3



Additional Notes:

*excluding 1 patient (6003) with surgery-related vision loss

**Two patients have so far been assessed at 18 months. One patient has gained 17 letters from baseline in the study eye and one letter in the non-study eye. The second patient has gained six letters from baseline in the study eye and 22 letters in the non-study eye.

ReNeuron

PHASE 2a EFFICACY RESULTS

INDIVIDUAL PATIENT IMPROVEMENTS AT 12 MONTHS

ETDRS change in treated eye from baseline 12 months post-treatment (n=7)



ReNeuron

NEXT STEPS

Collect long term data in normal dose subjects

- Most patient visits re-started post-Covid restrictions
- All 22 patients will be followed to at least 24 months post treatment

Recruit remaining patients in high dose expansion study

- First cohort complete - January 2021
- Enhancements in patient selection, dose, surgical technique and efficacy assessments

Further efficacy data to be presented at retinal conferences later this year

- AAO/ASRS/ARVO are the key conferences in ophthalmology

A single further clinical trial is planned before filing for marketing authorisation

- Randomised, not placebo controlled
- Three patient groups (high dose, low dose and observational cohort)

RENEURON TEAM AND CLINICAL ADVISERS

Olav Hellebø

Chief Executive Officer

Olav has held leadership roles internationally at big pharma companies, including Novartis and Schering Plough, and biotechs including Clavis Pharma ASA. Product launches include the TNF-blocker Cimzia whilst at specialty biopharma business UCB

Dr. Rick Beckman

Chief Medical Officer

After a career as an ophthalmologist in academics, then private practice, Rick moved into leadership roles at large companies including Allergan, Alcon and BD. He then moved on to serve as CMO at ophthalmology-focused biotechs including Neurotech, Ophthotech, and Clearside.

Clinical Advisors

Dr Jason Comander

Associate Director of the Inherited Retinal Disorders Service at Massachusetts Eye and Ear Infirmary and Assistant Professor of Ophthalmology at Harvard Medical School

Prof. Robert MacLaren

Professor of Ophthalmology, University of Oxford, directs research into new treatments for blindness. Co-founded Nighstar Therapeutics, which was acquired by Biogen.

Dr Timothy Stout

Chair of the Ophthalmology Department and Director of the Cullen Eye Institute at Baylor College of Medicine.

Dr Jordi Monés

Macula and Vitreorretinal Specialist and Researcher. Director of the Institut de la Màcula and the Director, Principal Investigator and one of the founder governors of the Barcelona Macula Foundation: Research for Vision.

Dr Karl Csaky

T. Boone Pickens Director, Molecular Ophthalmology Laboratory and Clinical Center of Innovation for Macular Degeneration.

ReNeuron

Pencoed Business Park | Pencoed
Bridgend | CF35 5HY | UK
T +44 (0) 203 819 8400 | E info@reneuron.com
www.reneuron.com
Ticker: RENE.L